Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Communication Strategies. Case Studies. Applied Knowledge.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
| 28 June 2013 | By Ansis Helmanis
The Board of Brazil's National Agency for Sanitary Surveillance (Anvisa) has opened a consultation on a proposal that would require companies to provide at least 180 days of advance notice to Anvisa prior to discontinuing, reducing or temporarily suspending the manufacture or importation of essential drugs.
In cases where the action is being taken due to technical reasons that could impact drug quality, safety and/or efficacy, notice would have to be provided to Anvisa within 24 hours of the suspension. The reasons for the manufacturer's action will be posted on the agency's website, with information as well as to expected resumption of manufacture or importation.
If there would be a risk of a drug shortage, Anvisa would expedite marketing approval of drug substitutes.
Anvisa: Consultation on Drug Shortages
Read all Breaking News from RegLink
Tags: Drug Shortages, Shortage, pharmaceutical, brazil, drug